1. Recent Advances in Synthesis and the Anticancer Activity of Benzothiazole Hybrids as Anticancer Agents
   Rajesh Kumar et al, 2022, Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I CrossRef
2. Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
   Valentín García-Gutiérrez et al, 2020, Journal of Clinical Medicine CrossRef
3. A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
   Rasha Kaddoura et al, 2023, Frontiers in Medicine CrossRef
4. Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation
   Sultan Tousif et al, 2023, Circulation Research CrossRef
5. Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
   Raquel Alves et al, 2021, Cancers CrossRef
6. Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia
   Dongfeng Zhang et al, 2021, Journal of Medicinal Chemistry CrossRef
7. Copper-Containing Nanoparticles and Organic Complexes: Metal Reduction Triggers Rapid Cell Death via Oxidative Burst
   Sergey A. Tsymbal et al, 2021, International Journal of Molecular Sciences CrossRef
8. Rhodanine Derivatives as Anticancer Agents: QSAR and Molecular Docking Studies
   Vesna Rastija et al, 2023, Anti-Cancer Agents in Medicinal Chemistry CrossRef
9. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
   Yammy Yung et al, 2021, International Journal of Molecular Sciences CrossRef
10. Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New Agents
    Massimo Breccia et al, 2022, Current Cancer Drug Targets CrossRef